Skip to main content

Acumen Pharmaceuticals, Inc. (ABOS) Stock

Acumen Pharmaceuticals, Inc. Stock Details, Movements and Public Alerts

Stock Details

Acumen Pharmaceuticals, Inc. (ABOS), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $2.47. Over the past 52 weeks, it has ranged between $0.99 and $3.60. This places the current price at 68.6% of its 52-week high and 149.5% above its 52-week low. Recent trading volume was recorded at 53,532. The 14-day Relative Strength Index (RSI) stands at 51.48, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $2.59 by 4.63%. Similarly, it is above its 200-day moving average of $2.14 by 15.42%. The MACD histogram is 0.01, indicating bullish momentum (MACD Line: -0.06, Signal Line: -0.07). There is currently 1 active alert set for ABOS by users.

52-Week Range

$3.60 - $0.99

-31.39% from high · +149.49% from low

Avg Daily Volume

311,577

20-day average

100-day avg: 651,413

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-1.66

Price to Book

2.07

EV/EBITDA

-0.73

EPS (TTM)

-$1.85

Q:How is ABOS valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is ABOS's risk profile compared to the market?
Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-114,556,000

Return on Equity

-93.23%

Return on Assets

-42.37%

Q:How profitable and efficient is ABOS's business model?
Profitability metrics are not available for this stock.
Q:What are ABOS's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$181.3M

Shares Outstanding

72.23M

Book Value/Share

$1.21

Asset Type

EQUITY

Q:What is ABOS's market capitalization and position?
Acumen Pharmaceuticals, Inc. has a market capitalization of $181.3M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 72.23M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does ABOS's price compare to its book value?
Acumen Pharmaceuticals, Inc.'s book value per share is $1.21, while the current stock price is $2.47, resulting in a price-to-book (P/B) ratio of 2.04. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$7.40

199.60% upside potential

Analyst Recommendations

Strong Buy

0

Buy

6

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for ABOS?
6 analysts cover ABOS with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $7.40 implies 199.6% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ABOS?
Current analyst recommendations:06 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: May 23, 2026, 02:19 AM

Technical Indicators

RSI (14-day)

51.48

Neutral

50-Day Moving Average

$2.59

-4.63% below MA-50

200-Day Moving Average

$2.14

15.42% above MA-200

MACD Line

-0.06

MACD Signal

-0.07

MACD Histogram

0.01

Bullish

Q:What does ABOS's RSI value tell investors?
The RSI (Relative Strength Index) for ABOS is currently 51.48, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this shows mixed signals requiring careful analysis.
Q:How should traders interpret ABOS's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.06 above the signal line at -0.07, with histogram at 0.01. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($2.59) is above the 200-day MA ($2.14), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: May 23, 2026, 12:47 AM

Active Alerts

Alert Condition
Golden Cross
Threshold
N/A
Created
Jan 26, 2026, 10:19 AM

Stay Ahead of the Market with Acumen Pharmaceuticals, Inc. Alerts

Set up price alerts for Acumen Pharmaceuticals, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.